Molecular imaging has experienced enormous advancements in the areas of imaging
technology, imaging probe and contrast development, and data quality, as well as machine …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, hel** to …

Background Innovations in imaging and molecular characterisation together with novel
treatment options have improved outcomes in advanced prostate cancer. However, we still …

Simple Summary Castration-resistant prostate cancer (CRPC) remains a significant medical
challenge, even with recent advancements in diagnosis and treatment. To improve patient …

Summary Background Enzalutamide and lutetium-177 [177 Lu] Lu-prostate-specific
membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic …

Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate
cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic …

The field of theranostics is rapidly advancing, driven by the goals of enhancing patient care.
Recent breakthroughs in artificial intelligence (AI) and its innovative theranostic applications …

Metastatic prostate cancer continues to be an incurable disease. Despite all the novel
therapies approved in the past two decades, overall patient outcomes remain relatively poor …

Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …

Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …